SCHEMBL5495221

SCHEMBL5495221

COc1cc2c(O)ncnc2cc1OCCCN1CCOCC1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 10/20 0.66
KDM1A O60341 1/20 0.65
KDM4E B2RXH2 1/20 0.65
AURKA O14965 2/20 0.64
RET P07949 2/20 0.63
KIF5B P33176 1/20 0.63
KDR P35968 7/20 0.63
EGFR P00533 6/20 0.63
FLT4 P35916 2/20 0.60
CIT O14578 1/20 0.60
GAK O14976 1/20 0.60
EPHB6 O15197 1/20 0.60
ABCC4 O15439 1/20 0.60
DAPK3 O43293 1/20 0.60
RIPK2 O43353 1/20 0.60
NR1I2 O75469 1/20 0.60
RPS6KA4 O75676 1/20 0.60
STK17B O94768 1/20 0.60
STK10 O94804 1/20 0.60
PRKD3 O94806 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25281864 1.00 SRC (0.66) SRCKDM1AKDM4EAURKARET
SCHEMBL1012553 0.94 RET (0.62) SRCKDM1AKDM4EAURKARET
SCHEMBL2921178 0.90 EHMT2 (0.65) SRCRETKIF5BKDREGFR
SCHEMBL13299046 0.89 AURKA (0.67) SRCKDM1AKDM4EAURKARET
SCHEMBL2475406 0.88 EHMT2 (0.64) RETKIF5BKDREGFRFLT4
SCHEMBL4422710 0.88 SRC (0.65) SRCKDM1AKDM4EAURKARET
SCHEMBL28480978 0.88 SRC (0.65) SRCKDM1AKDM4EAURKARET
SCHEMBL2770275 0.88 EGFR (0.67) SRCKDM1AKDM4EAURKARET
SCHEMBL4428694 0.88 SRC (0.65) SRCKDM1AKDM4EAURKARET
SCHEMBL29540227 0.88 SRC (0.65) SRCKDM1AKDM4EAURKARET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7262201-B1 For the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals ASTRAZENECA AB (SE) 2007-08-28 US disclosed
EP-1005470-B1 OXINDOLYLQUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS ASTRAZENECA AB (SE) 2007-08-01 EP disclosed
EP-1119567-B1 QUINAZOLINE DERIVATIVES ASTRAZENECA AB (SE) 2005-05-04 EP disclosed
EP-0912557-B1 OXINDOLE DERIVATIVES ASTRAZENECA AB (SE) 2003-07-09 EP disclosed
EP-0880508-B1 QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS ASTRAZENECA AB (SE) 2003-04-16 EP disclosed
US-6294532-B1 TREATMENT OF A NUMBER OF DISEASE STATES INCLUDING CANCER AND RHEUMATOID ARTHRITIS. ZENECA LIMITED (GB) 2001-09-25 US disclosed
EP-1119567-A1 QUINAZOLINE DERIVATIVES AstraZeneca AB (SE) 2001-08-01 EP disclosed
US-6265411-B1 ANGIOGENESIS INHIBITOR ZENECA LIMITED (GB) 2001-07-24 US disclosed
US-6184225-B1 ENDOTHELIAL GROWTH FACTOR INHIBITORS, ANGIOGENESIS INHIBITORS ZENECA LIMITED (GB) 2001-02-06 US disclosed
EP-1005470-A1 OXINDOLYLQUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS ZENECA LIMITED (GB) 2000-06-07 EP disclosed
WO-2000021955-A1 QUINAZOLINE DERIVATIVES ASTRAZENECA AB (SE) 2000-04-20 WO disclosed
EP-0912557-A1 OXINDOLE DERIVATIVES ZENECA LIMITED (GB) 1999-05-06 EP disclosed
WO-1999010349-A1 OXINDOLYLQUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS ZENECA LIMITED (GB) 1999-03-04 WO disclosed
EP-0880508-A1 QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS ZENECA LIMITED (GB) 1998-12-02 EP disclosed
WO-1997042187-A1 OXINDOLE DERIVATIVES ZENECA LIMITED (GB) 1997-11-13 WO disclosed
WO-1997030035-A1 QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS ZENECA LIMITED (GB) 1997-08-21 WO disclosed